No abstract available.
Edema* ; Gallbladder* ; Mucocutaneous Lymph Node Syndrome*

No abstract available.
Aged* ; Femoral Neck Fractures* ; Femur Neck* ; Humans

No abstract available.
Arthrography*

Flexor tendon grafting is a well-proved procedure for the restoration of tendon defects in the hand. The results are not entirely predictable, it offers a good expectation of successful outcome. Authors have performed the tendon graft in thirteen cases of flexor tendon injury of the hand during the period from September '79 to January '82 and evaluated the results. The followings were the results obtained. 1. Male was eleven, female was two. Age distribution is from 4 to 38 years. 2. Injured fingers were thumb 6, index 2, middle finger 4 and little finger 1 cases. The site of the primary injury was on area of Bunnell's Zone II in all cases. 3. Time interval from tendon injury to flexor tendon graft was 6 weeks to 19 months (average 5.6 months). 4. The results of tendon grafts rated as excellent 2 cases and good 3 cases in preoperative Good group; excellent 1, good 3 and fair 1 in “Scar” group; fair 1 and 1 poor in “Joint” group; fair 1 in “Salvage” group. In the thumbs, the results were better than in the fingers. 5. Degrading the postoperative results were flexion contracture in 3 cases, lack of flexion ROM in 2 cases and bowstringing in 2 cases. 6. Pinch power of the finger where tendon graft was performed was 52% of that of the opposite healthy finger. 7. As complication, bowstringing was observed in 2 cases and recurvatum deformity of the PIP joint in one case.
Age Distribution ; Congenital Abnormalities ; Contracture ; Female ; Fingers ; Hand ; Humans ; Joints ; Male ; Tendon Injuries ; Tendons ; Thumb ; Transplants

No abstract available.
Intermittent Positive-Pressure Ventilation* ; Tetanus*

No abstract available.
Cerebral Palsy* ; Equinus Deformity*

The 16 cases of patient with Hodgkin's disease admitted to Department of Pediatrics. Yonsei Cancer Center, Collage of Medicine, Yonsei University during 15 years from January 1975 to December 1989 were reviewed on the basis of clinical charicteristics, treatment and survival rate. The results were summerized as follows. 1) The mean age of patients was 7.6 4.1(range 2~15 years of age). 2) The clinical symptoms and signs were fever (50%), cervical lymphoadenpathy (44%), weight loss(25%), night sweat sweat(19%), hepatomegaly (13%) in order. 3) The stage by Ann Arbor classification revealed Stage I (19%), Stage II (37%), Stage III (19%), stage IV (25%). 4) The histologic subtype of the 14 cases confirmed by Rye Classification revealed that mixed cellularity type (57%) was the most common and lymphocyte predominant type (28%), nodular 5) The seven patients were treated by combind modality therapy, and the six patients by chemotherapy only and the three patients by radiotherapy only. 6) Overall 5 year survival rate was 69% in all patients, and 100% in Stage I, II, 67% in Stage III, but the patients of Stage IV were all died within 7 months.
Classification ; Drug Therapy ; Fever ; Hepatomegaly ; Hodgkin Disease* ; Humans ; Lymphocytes ; Pediatrics ; Radiotherapy ; Secale ; Survival Rate ; Sweat

No abstract available.
Humans ; Langerhans Cells* ; Prognosis*

PURPOSE: Glutathione S-transferases (GSTs) are polymorphic genes. Absence of enzyme activity due to homozygous or heterozygous deletion of the gene is associated with reduced detoxification of carcinogens and potentially increasing the risk of cancer. METHODS: DNA was extracted from bone marrow aspirates of 26 acute lymphoblastic leukemia (ALL) patients and from peripheral blood of 13 controls. PCR amplification was used to assess GSTM1, GSTT1, and GSTP1 at codon 105 and 114 genotypes for cases and controls. RESULTS: We investigated the polymorphisms within the GSTM1, GSTT1, and GSTP1 genes in children with ALL. The null (absence of both alleles) genotype for GSTM1 was 2.6-fold [odd ratio (OR), 0.38; 95% confidence interval (CI), 0.1-1.5; P=0.043] increased in children with ALL, whereas the frequency of GSTT1 null genotype in ALL cases was not statistically different from that of controls. GSTP1 Val105/Val105 genotype showed a 1.6-fold (OR, 0.63; 95% CI, 0.16-2.43; P=0.38) increase in ALL in comparison to the combined category of Ile105/Val105 and Ile105/Ile105 genotypes. CONCLUSION: Our results suggest that polymorphisms within genes of the GST superfamily (especiallly GSTM1 null type) may be increased in childhood ALL.
Bone Marrow ; Carcinogens ; Child ; Codon ; DNA ; Genotype ; Glutathione Transferase* ; Glutathione* ; Humans ; Polymerase Chain Reaction ; Precursor Cell Lymphoblastic Leukemia-Lymphoma*

PURPOSE: Vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) are associated with increased angiogenesis, growth, and metastasis in solid tumors. But, until today, the importance of theses factors on leukemia, especially childhood acute lymphocytic leukemia (ALL) has received limited attention. Therefore, this study examined the bone marrow plasma VEGF and bFGF levels in ALL patients and normal controls. PATIENTS AND METHODS: Bone marrow plasmas at diagnosis from 33 ALL patients (median age 5.9 years; range 1.8-13.9 years) were used for analysis. The bone marrow levels of bFGF and VEGF were determined by enzyme-linked immunosorbent assay (R & D Systems) and compared with the bone marrow levels of 7 healthy control subjects (median age 11.98 years; 6 months -13.6 years). RESULTS: Average VEGF was higher in relapse ALL (N=7, 216.6 +/- 79.9pg/mL) compared to standard (N=9, 36.8 +/- 12.1pg/mL) (p=0.013) or high risk ALL (N=17, 80.0 +/- 12.2pg/mL) (p=0.023). bFGF levels were also significantly higher in relapse than standard-, or high-risk ALL patients (relapse ALL; 48.6 +/- 15.4pg/mL, standard risk ALL; 18.9 +/- 5.5pg/mL, high risk ALL; 19.0 +/- 3.5pg/mL, normal control; 18.6 +/- 4.0pg/mL) (p=0.003). Three patients with refractory relapse and death had much higher VEGF and bFGF values (VEGF; 420.0 +/- 81.6pg/ mL, bFGF; 85.6 +/- 3.2pg/mL). CONCLUSION: Our data suggest that the increased levels of VEGF and bFGF in bone marrow may play an important role in prognosis of childhood ALL.